QIAGEN N.V.
QGEN
50.10−0.20 (−0.40%)Nov 12, 7:00 PM ET
Key stats
- Open
- 50.30
- Day high
- 50.31
- Day low
- 50.01
- Previous close
- 50.30
- Volume
- 4.24M
- VWAP
- 50.06
- 52-week high
- 57.82
- 52-week low
- 32.53
- Market cap
- 10.39B
- Shares out
- 206.07M
- Employees
- 5,500
- Listed
- 1996
About QIAGEN N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between life sciences and molecular diagnostics applications. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
Options · expiring Nov 20
Nov 12, 4:00 PM ET- Call open interest
- 10.2K
- Put open interest
- 5.4K
- Put/call
- 0.53
- At-the-money IV
- 4.1%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 47.50 put | 0.05 | Oct 28, 3:57 PM | 165 | 165 | — |
| 40 put | 0.39 | Oct 20, 11:49 AM | 50 | 1.1K | 96.2% |
| 50 call | 0.35 | Nov 12, 10:46 AM | 20 | 6.7K | 4.1% |
| 52.50 call | 0.04 | Nov 12, 11:11 AM | 20 | 226 | 23.4% |
| 50 put | 0.15 | Nov 12, 11:52 AM | 20 | 1.6K | 7.9% |
| 55 call | 0.05 | Nov 4, 3:38 PM | 15 | 2.0K | 39.8% |
Technicals
Massive · Nov 12, 2026- 50-day average46.38
- 200-day average42.47
- RSI (14 days)63.1
Short interest
Massive · Oct 30, 2026- Oct 30, 20266.40M shares · 1.0 days to cover
- Oct 15, 20267.20M shares · 3.3 days to cover
- Sep 30, 20267.68M shares · 3.6 days to cover
- Sep 15, 20267.66M shares · 4.5 days to cover
Dividends
Massive · Jul 7, 2026- Ex Jul 7, 2026, paid Jul 14, 20260.3500 · 1 a year
- Ex Jan 8, 20262.2900
- Ex Jul 2, 2025, paid Jul 10, 20250.2500 · 1 a year
- Ex Jan 29, 20251.2600
- Ex Jan 25, 20171.0400
Splits
Massive · Jan 29, 2025- Jan 29, 202535-for-36
- Jan 30, 202424.25-for-25
- Jan 25, 201726-for-27
News coverage
No stories about QIAGEN N.V. right now.